


## PCI-33380

Cat. No.:	HY-100335		
CAS No.:	1022899-36-0		
Molecular Formula:	C <sub>46</sub> H <sub>52</sub> BF <sub>2</sub> N <sub>11</sub> O <sub>3</sub>		
Molecular Weight:	855.78		
Target:	Btk		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 50 mg/mL (58.43 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration \ Mass	1 mg	5 mg	10 mg
	1 mM	1.1685 mL	5.8426 mL	11.6852 mL
5 mM	0.2337 mL	1.1685 mL	2.3370 mL	
10 mM	0.1169 mL	0.5843 mL	1.1685 mL	

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (2.92 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.5 mg/mL (2.92 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

PCI-33380 is an irreversible Bruton's Tyrosine Kinase (BTK) inhibitor (fluorescent probe).

#### IC<sub>50</sub> & Target

BTK<sup>[1][2]</sup>.

### REFERENCES

- [1]. Zuo Y, et al. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase. Sci Rep. 2015 Nov 4;5:16136.

---

[2]. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA